Literature DB >> 15004748

[Pain experience and pain therapy of tumor patients in the view of general practitioners].

H Janig1, W Pipam, S Lastin, R Sittl, G Bernatzky, R Likar.   

Abstract

AIM: The aim of the study presented in this paper is to find out how general practitioners evaluate their cancer patients' health, quality of life and type and extent of pain. In addition the study aims to get information about the training in pain therapy and palliative medicine.
METHODS: A representative sample of 440 of all Austrian general practitioners was interviewed via a standardized questionnaire. The consent for the questioning had been obtained by telephone.
RESULTS: The state of health and quality of life of the treated cancer patients are described as little satisfying and most unfavourably affected by the disease. The physicians suppose that the patients experience pain more intense than could be expected of them as endurable. Nevertheless the cancer patients appreciate pain therapy.
CONCLUSION: As a result the medical training in pain therapy and palliative medicine should be improved. At the same time the future general practitioners should gain psychological competences, which would consequently provide them with a broad spectrum of treatment needed when dealing with pain patients (suffering from cancer).

Entities:  

Mesh:

Year:  2005        PMID: 15004748     DOI: 10.1007/s00482-004-0326-2

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  22 in total

1.  Cancer care workers in Ontario: prevalence of burnout, job stress and job satisfaction.

Authors:  E Grunfeld; T J Whelan; L Zitzelsberger; A R Willan; B Montesanto; W K Evans
Journal:  CMAJ       Date:  2000-07-25       Impact factor: 8.262

2.  [Opioid therapy in Austria: results and analysis of a survey].

Authors:  G Bernatzky; W Pipam; G Pinter; G Mitterschiffthaler; R Likar
Journal:  Schmerz       Date:  1999-08-19       Impact factor: 1.107

3.  [Cancer pain management in Germany - results and analysis of a questionnaire].

Authors:  R Sabatowski; E R Arens; I Waap; L Radbruch
Journal:  Schmerz       Date:  2001-08       Impact factor: 1.107

4.  Stress among general practitioners and their spouses: a qualitative study.

Authors:  U Rout
Journal:  Br J Gen Pract       Date:  1996-03       Impact factor: 5.386

5.  [Results of a poll of cancer patients with respect to pain and quality of life].

Authors:  W Pipam; R Likar; J Klocker; G Bernatzky; T Platz; R Sittl; H Janig
Journal:  Schmerz       Date:  2002-12       Impact factor: 1.107

Review 6.  [Coping with occupational stresses in health professions].

Authors:  E Heim
Journal:  Psychother Psychosom Med Psychol       Date:  1993 Sep-Oct

7.  Perception of quality of life by patients, partners and treating physicians.

Authors:  K A Wilson; A J Dowling; M Abdolell; I F Tannock
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

8.  [A survey of physicians' knowledge about pain therapy with strong opioid analgesics].

Authors:  D Rothstein; M Strumpf; R Dertwinkel; B Donner; M Zenz
Journal:  Schmerz       Date:  1998-04-20       Impact factor: 1.107

9.  Do doctors undertreat pain?

Authors:  William Ruddick
Journal:  Bioethics       Date:  1997 Jul-Oct       Impact factor: 1.898

10.  Communication between physicians and with patients suffering from breast cancer.

Authors:  W J van der Kam; P J Branger; J H van Bemmel; B Meyboom-de Jong
Journal:  Fam Pract       Date:  1998-10       Impact factor: 2.267

View more
  2 in total

1.  [Ethic charter of the German Society for the Study of Pain (DGSS)].

Authors:  S Reiter-Theil; T Graf-Baumann; K Kutzer; H C Müller-Busch; R Stutzki; H C Traue; A Willweber-Strumpf; M Zimmermann; M Zenz
Journal:  Schmerz       Date:  2008-04       Impact factor: 1.107

2.  [Risk assessment in pain therapy].

Authors:  D Schoeffel; H R Casser; M Bach; H G Kress; R Likar; H Locher; W Steinleitner; M Strohmeier; H Brunner; R D Treede; W Zieglgänsberger; J Sandkühler
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.